The Phase 1, multicenter, open-label study to assess the efficacy and safety of two doses of the adeno-associated viral vector serotype 2 (AAVCAGsCD59) expressing sCD59 (CD59 molecule (CD59 blood group), soluble form) administered via intravitreal injection seven days after a single intravitreal injection of anti-VEGF is enrolling patients with treatment-naive wet AMD, but no results have been posted thus far (https://clinicaltrials.gov/study/NCT03585556?cond=Wet%20AMD&term=gene%20therapy&rank=4, accessed on 19 January 2024). This evidence concerns the gene VEGFA and wet macular degeneration.